Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Hear about what is happening at Harvard Medical School and where they are headed for future endeavors.
Examine the current obstacles in pricing, reimbursement, access and the healthcare & life sciences infrastructure. What is the current “state of play”? And perhaps most importantly, understand the changes in outcome for patients and the patient perspective.
Examine & Understand the impact of the growing industry pipeline, the evolution of clinical trial landscape and access to available real-world data on Oncology & therapeutic development
A look at a creative global collaboration to develop & commercialize Immuno-Oncology treatments.
Understand how diagnostics are enabling a more targeted approach to treat an increasing number of cancers.
How do you separate the hype from reality in today Drug Discovery? Cloud Pharmaceuticals is the leader of AI-based (augmented by data mining and computational chemistry) drug design and development. We will showcase here AI deployment and automation while maintaining chemical information that is crucial for drug discovery.
Clinical oncology is in crisis. Patients and physicians are
overwhelmed by a tsunami of research findings, conflicting expert
opinions, and a shortage of actionable data. Meanwhile trials cost too
much, take too long, and are too narrowly focused. Individual outcomes
vary widely and too many trials compete for too few patients. Learn
how AI can help bio-pharma slash the time and cost of developing
drugs, physicians make better decisions, and patients achieve superior
How will customizing treatments to individual needs impact the patient journey and treatment?
Explore how Oncolytic Viruses will increase the chances that patients will respond to Immunotherapies.
Sit in with Tyler Jacks and Amy Schulman as they discuss some new trends in cancer research and how the convergence of science and engineering is shaping the Koch Institute.